Results 21 to 30 of about 168,114 (189)

Clinical characteristics of patients with GFAP-IgG coexisting with AQP4-IgG or MOG-IgG [PDF]

Frontiers in Immunology
BackgroundGlial fibrillary acidic protein–immunoglobulin G (GFAP-IgG) can coexist with aquaporin-4–IgG (AQP4-IgG) or myelin oligodendrocyte glycoprotein–IgG (MOG-IgG).
Qingchen Li, Xinyun Chen
doaj   +2 more sources

Age-Related Clinical Presentation of MOG-IgG Seropositivity in Israel. [PDF]

Front Neurol, 2020
Introduction:Myelin oligodendrocyte glycoprotein (MOG) antibody associated disorders (MOGAD) have been recognized over the past 10 years as distinct inflammatory, demyelinating diseases of the central nervous system (CNS). Antibodies against MOG are found mostly in patients with optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and ...
Brill L, Ganelin-Cohen E, Dabby R, Rabinowicz S, Zohar-Dayan E, Rein N, Aloni E, Karmon Y, Vaknin-Dembinsky A.   +8 more
europepmc   +5 more sources

Anti-LGI1 encephalitis and co-existence of MOG-IgG: a case report and literature review [PDF]

Frontiers in Human Neuroscience
BackgroundAnti-leucine-rich glioma-inactivated-1 (LGI1) encephalitis is an autoimmune disorder characterized by antibodies that target LGI1 (LGI1-IgG). It typically presents with cognitive impairment, psychiatric disturbances, and faciobrachial dystonic ...
Xiaojiao Ci, Liuyu Lin, Yuqing Wu, Yifang Ma, Jie Lu   +4 more
doaj   +2 more sources

Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. [PDF]

Neurology, 2020
Myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) associated disorder (MOGAD) often manifests with recurrent CNS demyelinating attacks. The optimal treatment for reducing relapses is unknown. To help determine the efficacy of long-term immunotherapy in preventing relapse in patients with MOGAD, we conducted a multicenter retrospective ...
Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ.   +31 more
europepmc   +4 more sources

Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain [PDF]

Acta Neuropathologica Communications, 2014
Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) are present in some neuromyelitis optica patients who lack antibodies against aquaporin-4 (AQP4-IgG). The effects of neuromyelitis optica MOG-IgG in the central nervous system have not been investigated in vivo.
Saadoun, S, Waters, P, Owens, GP, Bennett, JL, Vincent, A, Papadopoulos, MC   +5 more
openaire   +6 more sources

MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder [PDF]

Frontiers in Neurology, 2018
Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have been found in some cases diagnosed as seronegative neuromyelitis optica spectrum disorder (NMOSD). MOG-IgG allowed the identification of a subgroup with a clinical course distinct from
Giordani Rodrigues dos Passos, Luana Michelli Oliveira, Bruna Klein da Costa, Samira Luisa Apostolos-Pereira, Dagoberto Callegaro, Kazuo Fujihara, Douglas Kazutoshi Sato, Douglas Kazutoshi Sato   +7 more
doaj   +2 more sources

Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria. [PDF]

Neurol Neuroimmunol Neuroinflamm
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a recently identified autoimmune demyelinating disorder of the CNS affecting both adults and children. Diagnostic criteria for MOGAD have recently been published. We aimed to validate the 2023 MOGAD diagnostic criteria in a real-world cohort of patients with atypical CNS ...
Forcadela M, Rocchi C, San Martin D, Gibbons EL, Wells D, Woodhall MR, Waters PJ, Huda S, Hamid S.   +8 more
europepmc   +3 more sources

Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis [PDF]

Neuro-Ophthalmology, 2019
Optic perineuritis can be a manifestation of infectious and systemic inflammatory disorders, but the majority of cases are idiopathic. Myelin oligodendrocyte glycoprotein (MOG)-IgG-positive optic neuritis has been reported to be associated with optic nerve sheath enhancement.
A Sebastian, Lopez-Chiriboga, Gregory, Van Stavern, Eoin P, Flanagan, Sean J, Pittock, Jim, Fryer, M Tariq, Bhatti, John J, Chen   +6 more
openaire   +3 more sources

Case Report: Papillophlebitis associated with MOG-IgG-associated optic neuritis. [PDF]

Front Med (Lausanne)
Optic neuritis is a common manifestation in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). However, its association with papillophlebitis is rare and has only been sporadically reported in the literature. Papillophlebitis is primarily characterized by central retinal vein occlusion (CRVO) and typically affects ...
Dai Y, Zhang S, Lou Y.
europepmc   +3 more sources

Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG-Associated Experimental Autoimmune Encephalomyelitis. [PDF]

Neurol Neuroimmunol Neuroinflamm, 2022
BACKGROUND AND OBJECTIVES Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) is a rare, autoimmune demyelinating CNS disorder, distinct from multiple sclerosis and neuromyelitis optica spectrum disorder.
Remlinger J, Madarasz A, Guse K, Hoepner R, Bagnoud M, Meli I, Feil M, Abegg M, Linington C, Shock A, Boroojerdi B, Kiessling P, Smith B, Enzmann V, Chan A, Salmen A.   +15 more
europepmc   +3 more sources